Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Arvinas Inc. (NASDAQ: ARVN ) is one of the best cancer stocks to invest in now . On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development. Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, affirming robust and differentiated activity in models of KRAS G12D-mutated cancer. It is also progressing with dose escalation in the Phase 1 trial of ARV-393 in patients with non-Hodgkin's lymphoma (NHL).393. “With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]Yahoo! Finance
- Arvinas (ARVN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARVN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sellMarketBeat
- Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.MarketBeat
ARVN
Earnings
- 2/24/26 - Miss
ARVN
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- ARVN's page on the SEC website